Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Control Form 5 Clear all
Completed Not applicable Interventional

The Confounding Burden of Psychological Impairments in Cervical Spine Surgery

NCT03183713
View directory record Official record
Conditions
Cervical Spine Disease, Psychological Impairment
Interventions
Cognitive Behavioral Therapy, Sham Therapy
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 30, 2026, 10:42 AM EDT
Recruiting Not applicable Interventional

Effects of High-Resistance Inspiratory Muscle Strength Training on Cardiorenal and Vascular Function in Youth and Young Adults With Type 2 Diabetes

NCT06936670
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Inspiratory Muscle Strength Training (IMST), Sham Training
Device
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

NCT01129427
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Placebo, Pantoprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 30, 2026, 10:42 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Lorazepam Effects on Neuroimaging Measures

NCT04671836
View directory record Official record
Conditions
Lorazepam, Neuroimaging
Interventions
Lorazepam 1Mg Tablet, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 30, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

NCT01528345
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dovitinib, Fulvestrant, Dovitinib Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

NCT01459198
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MEDI ΔM2-2 vaccine, Placebo vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 30, 2026, 10:42 AM EDT
Suspended Not applicable Interventional

Intermittent Theta Burst Stimulation for MDD

NCT02506127
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Neuronetics XPLOR system
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
22 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA and DHA From Two Dietary Supplements

NCT01908374
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
DHA-rich fish oil versus Phospholipid-rich fish oil
Dietary Supplement
Lead sponsor
Arctic Nutrition AS
Industry
Eligibility
18 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)

NCT01411774
View directory record Official record
Conditions
Obsessive-compulsive Disorder
Interventions
Cognitive-behavioral therapy, d-cycloserine, Pill placebo
Behavioral · Drug
Lead sponsor
University of South Florida
Other
Eligibility
7 Years to 17 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
2
States / cities
St. Petersburg, Florida • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

NCT05758896
View directory record Official record
Conditions
Contrast Induced Acute Kidney Injury
Interventions
Isuzinaxib (APX-115), Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

NCT01645280
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 30, 2026, 10:42 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections

NCT01110382
View directory record Official record
Conditions
Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain, Appendicitis, Rupture, Infection, Intestinal Perforation, Peritonitis, Ileus
Interventions
Doripenem, Meropenem placebo, Meropenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
San Diego, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 30, 2026, 10:42 AM EDT
Terminated Not applicable Interventional Results available

Stimulant Enhancement of Well-Being Therapy for Depression

NCT01478113
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Amphetamine/dextroamphetamine, Placebo, Well-being therapy
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 1 Interventional

Do Acid Sensing Ion Channels Contribute to Heartburn?

NCT01095133
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Heartburn
Interventions
Amiloride, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 59 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults

NCT03541499
View directory record Official record
Conditions
Pertussis, Pertussis Immunisation
Interventions
BPZE1, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dronabinol Naltrexone Treatment for Opioid Dependence

NCT01024335
View directory record Official record
Conditions
Opioid Dependence
Interventions
injectable naltrexone and dronabinol, Naltrexone and placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

NCT02315703
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose, gp140 DP High-dose, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT04666610
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 25 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tetravalent Chimeric Dengue Vaccine Trial

NCT01110551
View directory record Official record
Conditions
Dengue
Interventions
Placebo (SC), Placebo (ID), Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 30, 2026, 10:42 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes

NCT03885245
View directory record Official record
Conditions
Asthma, Obesity
Interventions
L-ctirulline, Matching Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

NCT02467400
View directory record Official record
Conditions
Osteoporosis, Age-Related
Interventions
Atenolol, Nebivolol, Propranolol, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

NCT00368251
View directory record Official record
Conditions
Unverricht-Lundborg Disease
Interventions
Placebo, BRV 2.5 mg, BRV 25 mg, BRV 50 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 30, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children

NCT01893554
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV ΔNS2 Δ1313 I1314L Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Months to 59 Months
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 30, 2026, 10:42 AM EDT